{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:49:01Z","timestamp":1740163741039,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/26580-9"],"award-info":[{"award-number":["2015\/26580-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since melanomas often retain wild type p53, we developed an adenoviral vector, AdRGD-PG, which provides robust transduction and transgene expression in response to p53. Previously, this vector was used for interferon-\u03b2 gene transfer in mouse models of melanoma, resulting in control of tumor progression, but limited cell killing. Here, the AdRGD-PG-hIFN\u03b2 vector encoding the human interferon-\u03b2 cDNA (hIFN\u03b2) was used to transduce human melanoma cell lines SK-MEL-05 and SK-MEL-147 (both wild type p53). In vitro, cell death was induced in more than 80% of the cells and correlated with elevated annexinV staining and caspase 3\/7 activity. Treatment with hIFN\u03b2 promoted cell killing in neighboring, non-transduced cells, thus revealing a bystander effect. In situ gene therapy resulted in complete inhibition of tumor progression for SK-MEL-147 when using nude mice with no evidence of hepatotoxicity. However, the response in Nod-Scid mice was less robust. For SK-MEL-05, tumor inhibition was similar in nude and Nod-Scid mice and was less efficient than seen for SK-MEL-147, indicating both cell type and host specific responses. The AdRGD-PG-hIFN\u03b2 vector provides extensive killing of human melanoma cells in vitro and a potent anti-tumor effect in vivo. This study provides a critical advance in the development of our melanoma gene therapy approach.<\/jats:p>","DOI":"10.1038\/s41598-020-74826-y","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T10:04:15Z","timestamp":1603274655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector"],"prefix":"10.1038","volume":"10","author":[{"given":"Taynah I. P.","family":"David","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto L. D.","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlous G.","family":"Lana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruan F. V.","family":"Medrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan E.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"74826_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","volume":"166","author":"A Lomas","year":"2012","unstructured":"Lomas, A., Leonardi-Bee, J. & Bath-Hextall, F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol. 166, 1069\u20131080. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10830.x (2012).","journal-title":"Br. J. Dermatol."},{"key":"74826_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004835.pub2","author":"MJ Sladden","year":"2009","unstructured":"Sladden, M. J. et al. Surgical excision margins for primary cutaneous melanoma. The Cochrane database of systematic reviews https:\/\/doi.org\/10.1002\/14651858.CD004835.pub2 (2009).","journal-title":"The Cochrane database of systematic reviews"},{"key":"74826_CR3","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch, C. M. et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635\u20133648 (2001).","journal-title":"J. Clin. Oncol."},{"key":"74826_CR4","first-page":"488","volume":"23","author":"S Bhatia","year":"2009","unstructured":"Bhatia, S., Tykodi, S. S. & Thompson, J. A. Treatment of metastatic melanoma: an overview. Oncology (Williston Park, N.Y.) 23, 488\u2013496 (2009).","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"74826_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11864-019-0666-x","volume":"20","author":"M Wada-Ohno","year":"2019","unstructured":"Wada-Ohno, M., Ito, T. & Furue, M. Adjuvant therapy for melanoma. Curr. Treat. Options Oncol. 20, 63. https:\/\/doi.org\/10.1007\/s11864-019-0666-x (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"74826_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030074","author":"P Lamichhane","year":"2019","unstructured":"Lamichhane, P. et al. Novel delivery systems for checkpoint inhibitors. Medicines (Basel, Switzerland) https:\/\/doi.org\/10.3390\/medicines6030074 (2019).","journal-title":"Medicines (Basel, Switzerland)"},{"key":"74826_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/10408363.2018.1499706","volume":"55","author":"M Music","year":"2018","unstructured":"Music, M., Prassas, I. & Diamandis, E. P. Optimizing cancer immunotherapy: is it time for personalized predictive biomarkers?. Crit. Rev. Clin. Lab. Sci. 55, 466\u2013479. https:\/\/doi.org\/10.1080\/10408363.2018.1499706 (2018).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"74826_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/humu.10179","volume":"21","author":"G Giglia-Mari","year":"2003","unstructured":"Giglia-Mari, G. & Sarasin, A. TP53 mutations in human skin cancers. Hum Mutat 21, 217\u2013228 (2003).","journal-title":"Hum Mutat"},{"key":"74826_CR9","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1038\/sj.onc.1206461","volume":"22","author":"E Sharpless","year":"2003","unstructured":"Sharpless, E. & Chin, L. The INK4a\/ARF locus and melanoma. Oncogene 22, 3092\u20133098. https:\/\/doi.org\/10.1038\/sj.onc.1206461 (2003).","journal-title":"Oncogene"},{"key":"74826_CR10","first-page":"1684","volume":"51","author":"CD James","year":"1991","unstructured":"James, C. D. et al. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Can. Res. 51, 1684\u20131688 (1991).","journal-title":"Can. Res."},{"key":"74826_CR11","first-page":"278","volume":"50","author":"J Miyakoshi","year":"1990","unstructured":"Miyakoshi, J. et al. Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons. Can. Res. 50, 278\u2013283 (1990).","journal-title":"Can. Res."},{"key":"74826_CR12","doi-asserted-by":"publisher","first-page":"10557","DOI":"10.1073\/pnas.89.21.10557","volume":"89","author":"JW Fountain","year":"1992","unstructured":"Fountain, J. W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. 89, 10557\u201310561 (1992).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74826_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","volume":"86","author":"H Zhang","year":"1996","unstructured":"Zhang, H., Chen, Z.-H. & Savarese, T. M. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-\u03b11, interferon-\u03b21, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 86, 22\u201328 (1996).","journal-title":"Cancer Genet. Cytogenet."},{"key":"74826_CR14","first-page":"1083","volume":"56","author":"Z-H Chen","year":"1996","unstructured":"Chen, Z.-H., Zhang, H. & Savarese, T. M. Gene deletion chemoselectivity: codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, and the \u03b1-and \u03b2-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Can. Res. 56, 1083\u20131090 (1996).","journal-title":"Can. Res."},{"key":"74826_CR15","doi-asserted-by":"publisher","first-page":"2353s","DOI":"10.1158\/1078-0432.ccr-05-2503","volume":"12","author":"MB Atkins","year":"2006","unstructured":"Atkins, M. B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12, 2353s\u20132358s. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-2503 (2006).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"74826_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ctrv.2007.10.003","volume":"34","author":"C Hamm","year":"2008","unstructured":"Hamm, C., Verma, S., Petrella, T., Bak, K. & Charette, M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat. Rev. 34, 145\u2013156. https:\/\/doi.org\/10.1016\/j.ctrv.2007.10.003 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"74826_CR17","doi-asserted-by":"publisher","first-page":"011123","DOI":"10.1002\/14651858.CD011123.pub2","volume":"2","author":"S Pasquali","year":"2018","unstructured":"Pasquali, S., Hadjinicolaou, A. V., Chiarion Sileni, V., Rossi, C. R. & Mocellin, S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst. Rev. 2, 011123. https:\/\/doi.org\/10.1002\/14651858.CD011123.pub2 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"74826_CR18","first-page":"16","volume":"43","author":"G Fierlbeck","year":"1992","unstructured":"Fierlbeck, G. et al. Intralesional therapy of melanoma metastases with recombinant interferon-beta. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 43, 16\u201321 (1992).","journal-title":"Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete"},{"key":"74826_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/10430340460732472","volume":"15","author":"J Yoshida","year":"2004","unstructured":"Yoshida, J. et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15, 77\u201386. https:\/\/doi.org\/10.1089\/10430340460732472 (2004).","journal-title":"Hum Gene Ther"},{"key":"74826_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/Jgm.1160","volume":"10","author":"T Wakabayashi","year":"2008","unstructured":"Wakabayashi, T. et al. A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J. Gene Med. 10, 329\u2013339. https:\/\/doi.org\/10.1002\/Jgm.1160 (2008).","journal-title":"J. Gene Med."},{"key":"74826_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12017-009-8059-0","volume":"11","author":"CS Shih","year":"2009","unstructured":"Shih, C. S. et al. AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromol. Med. 11, 43\u201352. https:\/\/doi.org\/10.1007\/s12017-009-8059-0 (2009).","journal-title":"Neuromol. Med."},{"key":"74826_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/jjco\/hyn114","volume":"38","author":"K Matsumoto","year":"2008","unstructured":"Matsumoto, K. et al. A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn. J. Clin. Oncol. 38, 849\u2013856. https:\/\/doi.org\/10.1093\/jjco\/hyn114 (2008).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"74826_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/sj.gt.3301453","volume":"8","author":"H Mizuguchi","year":"2001","unstructured":"Mizuguchi, H. et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 8, 730\u2013735. https:\/\/doi.org\/10.1038\/sj.gt.3301453 (2001).","journal-title":"Gene Ther."},{"key":"74826_CR24","doi-asserted-by":"publisher","first-page":"17017","DOI":"10.1038\/cddiscovery.2017.17","volume":"3","author":"A Hunger","year":"2017","unstructured":"Hunger, A. et al. Reestablishment of p53\/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discov. 3, 17017. https:\/\/doi.org\/10.1038\/cddiscovery.2017.17 (2017).","journal-title":"Cell Death Discov."},{"key":"74826_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1089\/hum.2016.139","volume":"28","author":"RE Tamura","year":"2017","unstructured":"Tamura, R. E. et al. Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector. Hum. Gene Ther. 28, 639\u2013653. https:\/\/doi.org\/10.1089\/hum.2016.139 (2017).","journal-title":"Hum. Gene Ther."},{"key":"74826_CR26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/15384047.2016.1235655","volume":"17","author":"RE Tamura","year":"2016","unstructured":"Tamura, R. E., da Silva Soares, R. B., Costanzi-Strauss, E. & Strauss, B. E. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy. Cancer Biol. Ther. 17, 1221\u20131230. https:\/\/doi.org\/10.1080\/15384047.2016.1235655 (2016).","journal-title":"Cancer Biol. Ther."},{"key":"74826_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virol.2007.11.015","volume":"371","author":"MC Bajgelman","year":"2008","unstructured":"Bajgelman, M. C. & Strauss, B. E. Development of an adenoviral vector with robust expression driven by p53. Virology 371, 8\u201313 (2008).","journal-title":"Virology"},{"key":"74826_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/cgt.2013.23","volume":"20","author":"C Merkel","year":"2013","unstructured":"Merkel, C., Medrano, R., Barauna, V. & Strauss, B. Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Ther. 20, 317 (2013).","journal-title":"Cancer Gene Ther."},{"key":"74826_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00262-016-1807-8","volume":"65","author":"RF Medrano","year":"2016","unstructured":"Medrano, R. F. et al. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy. Cancer Immunol. Immunother. 65, 371\u2013382. https:\/\/doi.org\/10.1007\/s00262-016-1807-8 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"74826_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.tranon.2016.09.011","volume":"9","author":"JP Catani","year":"2016","unstructured":"Catani, J. P. et al. Intratumoral immunization by p19Arf and Interferon-beta gene transfer in a heterotopic mouse model of lung carcinoma. Transl Oncol 9, 565\u2013574. https:\/\/doi.org\/10.1016\/j.tranon.2016.09.011 (2016).","journal-title":"Transl Oncol"},{"key":"74826_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00008390-199402000-00006","volume":"4","author":"AP Albino","year":"1994","unstructured":"Albino, A. P. et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4, 35\u201345. https:\/\/doi.org\/10.1097\/00008390-199402000-00006 (1994).","journal-title":"Melanoma Res."},{"key":"74826_CR32","first-page":"4285","volume":"57","author":"PM O'Connor","year":"1997","unstructured":"O\u2019Connor, P. M. et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285\u20134300 (1997).","journal-title":"Cancer Res."},{"key":"74826_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1006\/mthe.2001.0464","volume":"4","author":"XQ Qin","year":"2001","unstructured":"Qin, X. Q., Beckham, C., Brown, J. L., Lukashev, M. & Barsoum, J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol. Therapy: J. Am. Soc. Gene Therapy 4, 356\u2013364. https:\/\/doi.org\/10.1006\/mthe.2001.0464 (2001).","journal-title":"Mol. Therapy: J. Am. Soc. Gene Therapy"},{"key":"74826_CR34","first-page":"258","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. Ser. B-Biol. Sci. 147, 258\u2013267 (1957).","journal-title":"Proc. R. Soc. Lond. Ser. B-Biol. Sci."},{"key":"74826_CR35","first-page":"1821","volume":"7","author":"M Chawla-Sarkar","year":"2001","unstructured":"Chawla-Sarkar, M., Leaman, D. W. & Borden, E. C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL\/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 7, 1821\u20131831 (2001).","journal-title":"Clin. Cancer Res."},{"key":"74826_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/107999004323034105","volume":"24","author":"SH Juang","year":"2004","unstructured":"Juang, S. H. et al. IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J. Interferon Cytokine Res. Off. J. Int. Soc. Int. Cytokine Res. 24, 231\u2013243. https:\/\/doi.org\/10.1089\/107999004323034105 (2004).","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Int. Cytokine Res."},{"key":"74826_CR37","first-page":"245","volume":"3","author":"D Kavanagh","year":"2005","unstructured":"Kavanagh, D. et al. Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surg. J. R. Colleges Surg. Edinb. Irel. 3, 245\u2013256 (2005).","journal-title":"Surg. J. R. Colleges Surg. Edinb. Irel."},{"key":"74826_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11864-003-0020-0","volume":"4","author":"A Terando","year":"2003","unstructured":"Terando, A., Sabel, M. S. & Sondak, V. K. Melanoma: adjuvant therapy and other treatment options. Curr. Treat. Options Oncol. 4, 187\u2013199 (2003).","journal-title":"Curr. Treat. Options Oncol."},{"key":"74826_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","volume":"59","author":"J Fogh","year":"1977","unstructured":"Fogh, J., Fogh, J. M. & Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59, 221\u2013226 (1977).","journal-title":"J. Natl. Cancer Inst."},{"key":"74826_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00052605","volume":"8","author":"JE Price","year":"1990","unstructured":"Price, J. E. & Zhang, R. D. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev. 8, 285\u2013297 (1990).","journal-title":"Cancer Metastasis Rev."},{"key":"74826_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/s-2008-1043947","volume":"209","author":"G Baersch","year":"1997","unstructured":"Baersch, G. et al. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klinische P\u00e4diatrie 209, 178\u2013185 (1997).","journal-title":"Klinische P\u00e4diatrie"},{"key":"74826_CR42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0002-9440(10)63162-8","volume":"164","author":"S-Y Huang","year":"2004","unstructured":"Huang, S.-Y., Tien, H.-F., Su, F.-H. & Hsu, S.-M. Nonirradiated NOD\/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. Am. J. Pathol. 164, 747\u2013756 (2004).","journal-title":"Am. J. Pathol."},{"key":"74826_CR43","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano, R. F. V., Hunger, A., Mendonca, S. A., Barbuto, J. A. M. & Strauss, B. E. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 8, 71249\u201371284. https:\/\/doi.org\/10.18632\/oncotarget.19531 (2017).","journal-title":"Oncotarget"},{"key":"74826_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ab.2006.04.032","volume":"354","author":"HH Peng","year":"2006","unstructured":"Peng, H. H. et al. A rapid and efficient method for purification of recombinant adenovirus with arginine\u2013glycine\u2013aspartic acid-modified fibers. Anal. Biochem. 354, 140\u2013147 (2006).","journal-title":"Anal. Biochem."},{"key":"74826_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/stem.160166","volume":"16","author":"DL Greiner","year":"1998","unstructured":"Greiner, D. L., Hesselton, R. A. & Shultz, L. D. SCID mouse models of human stem cell engraftment. Stem Cells 16, 166\u2013177 (1998).","journal-title":"Stem Cells"},{"key":"74826_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148\u2013154 (1989).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"74826_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41434-019-0071-x","volume":"27","author":"RE Tamura","year":"2020","unstructured":"Tamura, R. E., Lana, M. G., Costanzi-Strauss, E. & Strauss, B. E. Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth. Gene Ther. 27, 15\u201326. https:\/\/doi.org\/10.1038\/s41434-019-0071-x (2020).","journal-title":"Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74826-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:09:50Z","timestamp":1670364590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74826-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74826"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74826-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17893"}}